We are live on ! Find out more
LEGN icon

Legend Biotech

206 hedge funds and large institutions have $5.16B invested in Legend Biotech in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 92 increasing their positions, 58 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

201% more call options, than puts

Call options by funds: $58.4M | Put options by funds: $19.4M

59% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 58

3% more funds holding

Funds holding: 200 → 206 (+6)

0.09% less ownership

Funds ownership: 47.18% → 47.09% (-0.09%)

4% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 27

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

16% less capital inflows, than outflows

Capital inflows: $460M | Capital outflows: $551M

Holders
206
Holders Change
+6
Holders Change %
+3%
% of All Funds
3%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.1%
New
26
Increased
92
Reduced
58
Closed
27
Calls
$58.4​M
Puts
$19.4​M
Net Calls
+$39​M
Net Calls Change
+$40.4​M

LEGN Hedge Fund Activity: Q4 2023 in Review

206 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q4 2023, worth a combined $5.16B — down 11% from $5.78B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of LEGN and 26 opened new positions — a net loss of 1 holder — while 58 trimmed existing stakes and 92 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $70.6M. The largest seller was Fidelity Investments, cutting an estimated $197M.

  • 206 institutional investors held Legend Biotech (LEGN) as of Q4 2023, up from 200 in Q3 2023.
  • Funds reported $5.16B of Legend Biotech stock for Q4 2023, down 11% quarter-over-quarter.
  • 26 funds opened new Legend Biotech positions in Q4 2023 and 27 closed out, a net change of -1 holder.
  • The largest Legend Biotech buyer in Q4 2023 was T. Rowe Price Associates, an estimated $70.6M added.
  • The largest Legend Biotech seller in Q4 2023 was Fidelity Investments, an estimated $197M sold.

Based on aggregated 13F filings for Q4 2023.